Heterocyclic scaffolds: centrality in anticancer drug development

I Ali, M Nadeem Lone, ZA Al-Othman… - Current drug …, 2015 - ingentaconnect.com
Cancer has been cursed for human beings for long time. Millions people lost their lives due
to cancer. Despite of the several anticancer drugs available, cancer cannot be cured; …

Role of the VEGF/VEGFR axis in cancer biology and therapy

A Rapisarda, G Melillo - Advances in cancer research, 2012 - Elsevier
New vessel formation (angiogenesis) is an essential physiological process for embryologic
development, normal growth, and tissue repair. Angiogenesis is tightly regulated at the …

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

CN Sternberg, ID Davis, J Mardiak… - Journal of clinical …, 2010 - ascopubs.org
Purpose Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth
factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double …

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

RJ Motzer, TE Hutson, P Tomczak… - Journal of clinical …, 2009 - ascopubs.org
Purpose A randomized, phase III trial demonstrated superiority of sunitinib over interferon
alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for …

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

M McTigue, BW Murray, JH Chen… - Proceedings of the …, 2012 - National Acad Sciences
Analyses of compounds in clinical development have shown that ligand efficient-molecules
with privileged physical properties and low dose are less likely to fail in the various stages of …

[HTML][HTML] Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression

M Chittezhath, MK Dhillon, JY Lim, D Laoui, IN Shalova… - Immunity, 2014 - cell.com
Monocytes and macrophages are major components of the tumor microenvironment, but
their contributions to human cancer are poorly understood. We used molecular profiling …

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance

KJ Gotink, HJ Broxterman, M Labots, RR De Haas… - Clinical Cancer …, 2011 - AACR
Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an
important clinical problem, but its underlying mechanisms are largely unknown. We …

Protein kinase inhibitors: contributions from structure to clinical compounds

LN Johnson - Quarterly reviews of biophysics, 2009 - cambridge.org
Protein kinases catalyse key phosphorylation reactions in signalling cascades that affect
every aspect of cell growth, differentiation and metabolism. The kinases have become prime …

Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST

M Nishino, JP Jagannathan… - American Journal of …, 2012 - Am Roentgen Ray Soc
OBJECTIVE. The purpose of this article is to review cancer-and therapy-specific tumor
response assessment criteria used in clinical trials and in practice, with illustrative case …

Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib

AD Lipworth, C Robert, AX Zhu - Oncology, 2009 - karger.com
Abstract Hand-foot syndrome (HFS), also called hand-foot skin reaction, palmar-plantar
erythrodysesthesia, acral erythema, and Burgdorf reaction, is a dose-limiting cutaneous …